Myokardia (NASDAQ:MYOK) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating in a note issued to investors on Thursday, ValuEngine reports.
MYOK has been the topic of several other reports. BidaskClub cut Myokardia from a "buy" rating to a "hold" rating in a research note on Wednesday. Wedbush raised their target price on Myokardia from $90.00 to $127.00 in a research note on Tuesday, May 12th. Morgan Stanley lifted their price objective on Myokardia from $83.00 to $87.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. BMO Capital Markets lifted their price objective on Myokardia from $90.00 to $148.00 and gave the company an "outperform" rating in a research report on Thursday, May 14th. Finally, Citigroup lifted their price objective on Myokardia from $87.00 to $125.00 and gave the company a "buy" rating in a research report on Tuesday, May 12th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has a consensus rating of "Buy" and an average target price of $121.70.
NASDAQ MYOK opened at $93.84 on Thursday. The stock has a market capitalization of $4.52 billion, a PE ratio of -14.07 and a beta of 2.33. Myokardia has a 1 year low of $42.65 and a 1 year high of $126.30. The business's 50-day moving average is $103.22 and its 200 day moving average is $73.53.
Myokardia (NASDAQ:MYOK) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($1.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.36) by ($0.14). As a group, equities analysts anticipate that Myokardia will post -6.29 EPS for the current year.
In other news, Director Mary B. Cranston sold 21,629 shares of the business's stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $96.60, for a total value of $2,089,361.40. Following the sale, the director now directly owns 371 shares of the company's stock, valued at approximately $35,838.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Anastasios Gianakakos sold 1,500 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $50.00, for a total value of $75,000.00. Following the completion of the sale, the chief executive officer now directly owns 77,796 shares in the company, valued at $3,889,800. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,434 shares of company stock worth $5,119,583. Insiders own 5.20% of the company's stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Myokardia in the 1st quarter worth approximately $68,000. Exane Derivatives bought a new stake in shares of Myokardia in the 1st quarter worth approximately $84,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Myokardia by 11.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,762 shares of the biotechnology company's stock worth $176,000 after acquiring an additional 380 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in Myokardia by 3.7% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,947 shares of the biotechnology company's stock worth $185,000 after acquiring an additional 140 shares during the last quarter. Finally, Strs Ohio raised its holdings in Myokardia by 33.3% in the 1st quarter. Strs Ohio now owns 4,400 shares of the biotechnology company's stock worth $206,000 after acquiring an additional 1,100 shares during the last quarter.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Recommended Story: When can a hold rating present a buying opportunity?
To view ValuEngine's full report, visit ValuEngine's official website.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Gambling Stocks Ready For a Rebound
If you didn’t believe that gambling stocks are a worthwhile investment, consider this. The Business Research Company projects the global gambling market to reach $565.4 billion through 2022. That assumes that the industry will continue growing at is annual rate of 5.9%.
The gambling industry is composed of many segments. There are casinos, lotteries, and the now legalized segment of sports betting. But gambling is also broken down into offline gambling, online gambling and even virtual reality gambling. In fact, virtual reality gambling is projected to grow at an annual rate of 21.5% until 2022.
But virtual reality is only one of a number of emerging technologies that are changing the “traditional” face of the gambling industry. There are now hybrid games – the combination of online and land-based games and even augmented reality games.
And don’t forget about fantasy sports. Fantasy sports has created an entire industry and it wasn’t created for one person to have bragging rights over their buddies. Fantasy sports is a multi-million industry.
But like many other segments of the economy, gambling stocks were hit hard by the Covid-19 pandemic. Not only were casinos closed, but live sports were also put on hold. This dried up many of the traditional avenues of gambling, and gambling stocks sank lower as a result.
However, the global economy is starting to re-open. And while it was thought that casinos would be one of the last to come back, there are casinos that are starting to re-open. And, it’s becoming more and more likely that there will be live sports (likely without fans initially) sooner rather than later. And that will open up the fantasy sports market.
These stocks tend to move quickly. So now is the time to take action. That’s why we’ve created this special presentation that highlights 6 gambling stocks that are ready for a rebound. The sell-off was real, but so will the comeback. And when it does, these stocks may cost much more than they do now.
View the "6 Gambling Stocks Ready For a Rebound".